

1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?
 - Azacitidine monotherapy
 - Low dose cytarabine (LoDAC) monotherapy
 - Venetoclax + azacitidine
 - Venetoclax + LoDAC
 - Ivosidenib
 - Intensive chemotherapy-based regimen
 - Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
 - Best supportive care
 - Other
 - Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Answer:

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	0
(LoDAC) monotherapy	0
Venetoclax + azacitidine	<5
Venetoclax + LoDAC	<5
Ivosidenib	0
Intensive chemotherapy-based regimen	<5
Best supportive care	<5
Other	0